• Contact Us
  • Register
  • Sign In
PHACS PHACS
  • Home
  • About Us
    • Mission and Values
    • Leadership
    • Participating Organizations
    • Funding
    • Clinical Site Feature Profiles
    • PHACS Puerto Rico Hurricane Relief
    • Inspiration Hub
    • In Memoriam
    • Contact Us
  • Our Research
    • Studies
    • Support Cores
    • Working Groups and Task Forces
    • Resources for Researchers
    • The George R. Seage III Early Career Investigator Award
    • Research Network Partners
    • Collaborate with Us
    • Participate in the Study
    • Non-Disclosure Agreement (NDA)
  • Findings
    • Publications
    • PHACS in the News
    • Infographics Series
    • Research Summaries
    • Resúmenes de las Investigaciones
  • Community
    • COVID-19 and PHACS
    • Adult Community Advisory Board
    • Peers United Group (PUG)/YACAB
    • Health Education Resources
    • PHACS Film Series
    • Quarterly Digest
  • Contact Us
  • Register
  • Sign In
  • You are here:  
  • Home
  • / Our Research
  • / Studies
  • / SMARTT

SMARTT

The Surveillance and Monitoring for ART Toxicities (SMARTT) Protocol evaluates the long-term safety of antiretroviral (ARV) medications taken during pregnancy among women living with HIV (WLHIV) and their children born without HIV. The PHACS SMARTT study is the largest study of pregnant WLHIV in the United States, and one of the only large studies in the world to follow children born to WLHIV beyond infancy.  

A major focus of the SMARTT study is the evaluation of effects of maternal exposures to ARVs, prescribed medications, and substance use during pregnancy on health outcomes in their infants and children. These health outcomes cross a wide spectrum of domains including:

  • Growth
  • Neurodevelopment
  • Cardiometabolic
  • Hearing and language
  • Neurologic functioning

Although the primary focus of SMARTT is the evaluation of safety of in utero ARV exposures on children, the information we collect about mothers during pregnancy and postpartum can also be used to study critical issues facing WLHIV, including: 

  • Reproductive health
  • Important pregnancy complications such as gestational diabetes, pre-eclampsia, anemia, and hypertensive disorders of pregnancy
  • Postpartum mental health
  • The role of other factors such as environmental exposures during pregnancy on post-pregnancy health outcomes

Findings from the SMARTT study have informed national and international treatment guidelines of WLHIV during pregnancy.  The SMARTT study aims to enroll 200 mothers and their babies each year and will continue to follow child participants as follows:

  • All children followed to age 5
  • A smaller group of children followed to age 17
Our Research
Studies
AMP Up Series
SMARTT
TERBO BRAIN
HOPE
Support Cores
Working Groups and Task Forces
Resources for Researchers
The George R. Seage III Early Career Investigator Award
Research Network Partners
Collaborate with Us
Participate in the Study
Non-Disclosure Agreement (NDA)

Confidentiality Policy   |   Terms of Use   |   Powered by Emerson Media

National Institutes of Health

Introducing the PHACS Member Area (BETA)